This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Gaines, A. R. Articles by Varricchio, F. Search for Related Content PubMed PubMed Citation Articles by Gaines, A. R. Articles by Varricchio, F. Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information Multiple Sclerosis Social Bookmarking                   What's this?

Interferon beta-1b injection site reactions and necroses

Division of Biostatistics and Epidemiology, Office of Establishment Licensing and Product Surveillance, Center for Biologics Evaluation and Research, Food and Drug Administration, 1401 Rockville Pike, Rockville, Maryland 20852-1448, USA

Frederick Varricchio

Division of Biostatistics and Epidemiology, Office of Establishment Licensing and Product Surveillance, Center for Biologics Evaluation and Research, Food and Drug Administration, 1401 Rockville Pike, Rockville, Maryland 20852-1448, USA

We conducted a comprehensive review of selected adverse event reports that were submitted to the Food and Drug Administration (FDA) for interferon beta-1b during the first 30 months following licensure. The adverse events reviewed were injection site reactions, injection site necroses, and non-injection site necroses. These adverse events were selected because of the relative frequency of injection site reactions and because of the severity and sequelae of certain injection site and non-injection site necroses. Our review enabled us to characterize the clinical presentation and the treatment received, which were not described in the package insert or by the IFNB (interferon beta-1b) Multiple Sclerosis Study Group publication. The time of onset of the adverse events ranged from 1-29 months after initiation of interferon beta-1b treatment, with a mean of 1 month. In general, the more clinically significant adverse events (i.e., injection site necrosis and non-injection site necrosis) developed more slowly than the injection site reactions. Greater than 85% of the adverse events presented with one or two signs/symptoms, although the number of signs/symptoms ranged from 1-8. No predominance of treatments for the adverse events was observed. The most striking finding was that the overall sex ratio, which could be due to reporting artifacts, was 8.1: 1 female: male.

Key Words: interferon beta-1b adverse events

Multiple Sclerosis, Vol. 4, No. 2, 70-73 (1998)
DOI: 10.1177/135245859800400205


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				K. Baum, C. O'Leary, F. Coret Ferrer, E. Klimova, L. Prochazkova, J. Bugge, and for the BRIGHT Study Group Comparison of injection site pain and injection site reactions in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a or 1b Multiple Sclerosis, November 1, 2007; 13(9): 1153 - 1160. [Abstract] [PDF]

				E M Frohman, K Brannon, S. Alexander, D Sims, J T Phillips, S O'Leary, K Hawker, and M K Racke Disease modifying agent related skin reactions in multiple sclerosis: prevention, assessment, and management Multiple Sclerosis, June 1, 2004; 10(3): 302 - 307. [Abstract] [PDF]

				K Gottberg, A Gardulf, and S Fredrikson Interferon-beta treatment for patients with multiple sclerosis: the patients' perceptions of the side-effects Multiple Sclerosis, October 1, 2000; 6(5): 349 - 354. [Abstract] [PDF]

				E. U. Walther and R. Hohlfeld Multiple sclerosis: Side effects of interferon beta therapy and their management Neurology, November 1, 1999; 53(8): 1622 - 1622. [Abstract] [Full Text] [PDF]